Asia-Pacific Glucagon-like Peptide-1 (GLP-1) Agonists Companies

This report lists the top Asia-Pacific Glucagon-like Peptide-1 (GLP-1) Agonists companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Asia-Pacific Glucagon-like Peptide-1 (GLP-1) Agonists industry.

Asia-Pacific GLP-1 Agonists Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Asia-Pacific Glucagon-like Peptide-1 (GLP-1) Agonists Top Companies

  1. AstraZeneca

  2. Eli Lilly and Company

  3. Novo Nordisk

  4. Sanofi

  5. Biocon

*Disclaimer: Top companies sorted in no particular order

Asia-Pacific Glucagon-like Peptide-1 (GLP-1) Agonists Market Major Players

Asia-Pacific Glucagon-like Peptide-1 (GLP-1) Agonists Market Concentration

Asia-Pacific Glucagon-like Peptide-1 (GLP-1) Agonists Market Concentration

Asia-Pacific Glucagon-like Peptide-1 (GLP-1) Agonists Company List

  • Novo Nordisk

  • AstraZeneca

  • Eli Lilly and Company

  • Sanofi

  • Biocon

  • Novartis


Specific to Asia-Pacific Glucagon-like Peptide-1 (GLP-1) Agonists Market
Need More Details on Market Players and Competiters?
Download PDF

Asia-Pacific Glucagon-like Peptide-1 (GLP-1) Agonists Market Report Snapshots